Dr. Battiwalla directs Blood Cancer Outcomes Research across the Sarah Cannon Transplant & Cellular Therapy Network and practices at TriStar Centennial Medical Center in Nashville. Every new patient undergoes high-sensitivity measurable-residual-disease testing, broad next-generation sequencing, and pharmacogenomic screening; these data feed weekly molecular conferences where transplant, cellular-therapy, and supportive-care experts align conditioning intensity, graft source, and investigational options to each disease biology.
His translational portfolio has shaped contemporary practice. NIH-funded studies defined late cardiovascular and endocrine toxicities after allogeneic transplant and guided the NIH Late Effects Consensus still used worldwide. He later led multicentre analyses that validated outpatient CAR T-cell administration and documented comparable cytokine-release-syndrome control to inpatient care, a result now incorporated in Sarah Cannon protocols.
Education and equity frame his clinical mission. Dr. Battiwalla mentors fellows through the International CML Foundation “CURE” programme and co-designs bilingual survivorship workshops that pair graft-versus-host self-management with tele-monitoring, lowering unplanned readmissions across fifteen network centres. His outcomes-research unit mines linked electronic-health-record and registry data to benchmark transplant quality and accelerate learning across the United States and the United Kingdom.
Locations:
Cancer Treated:
Insurance
Insurance changes all the time, so please call and confirm if your insurance is accepted.
- AetnaAlliant Health PlansArkansas Blue Cross and Blue ShieldAspirus Health PlanBlue Cross and Blue Shield of Kansas CityBlue Cross Blue Shield of ArizonaBlue Cross Blue Shield of MassachusettsBlue Cross Blue Shield of MichiganCignaCMS MedicareDelta DentalElevanceEMI HealthExcellus BlueCross BlueShieldHCSCHumanaKY State MedicaidRegence Health PlansUnited Healthcare